Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QuidelOrtho Corporation (Nasdaq: QDEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an issuer in the in vitro diagnostics and medical device manufacturing space, QuidelOrtho uses these filings to report on its financial condition, capital structure, material agreements and other significant events.
Investors can review current reports on Form 8‑K, where QuidelOrtho furnishes press releases announcing quarterly financial results, earnings conference calls and stockholder letters discussing recent performance and strategic priorities. For example, 8‑K filings in November 2025 reference third‑quarter results and a stockholder communication, while an August 21, 2025 8‑K details a Credit Agreement that established senior secured term loan A and term loan B facilities and a revolving credit facility with a syndicate of lenders.
Alongside 8‑Ks, users can also access annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide more comprehensive information on QuidelOrtho’s business, including its diagnostic segments in clinical chemistry, immunoassay, immunohematology and molecular testing. These reports typically include discussions of risk factors, research and development spending, and other elements that shape the company’s long‑term outlook.
For those interested in governance and ownership, proxy statements and beneficial ownership reports (such as Forms 3, 4 and 5) can be used to analyze executive and director holdings and transactions, although specific examples are not detailed here. Together, these documents form a record of how QuidelOrtho communicates with regulators and investors about its operations and capital decisions.
Stock Titan enhances this information by pairing real‑time EDGAR updates with AI‑powered summaries that explain the key points of long filings in plain language. Users can quickly see what each new 10‑K, 10‑Q, 8‑K or Form 4 means for QuidelOrtho without reading every page, while still having direct access to the full text for deeper review.
QuidelOrtho Corp President and CEO Brian J. Blaser reported equity compensation activity tied to restricted stock units. On January 29, 2026, 21,446 restricted stock units vested, resulting in an acquisition of 21,446 shares of common stock at $0 per share.
To cover tax withholding on this vesting, 7,755 common shares were withheld by the issuer at $27.41 per share. After these transactions, Blaser directly beneficially owned 25,142 common shares and indirectly held 29,533 shares through a trust. The filing also notes 42,892 restricted stock units remain unvested, scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.
QuidelOrtho Corp (QDEL) director Kenneth J. Widder reported an option exercise and related share sale. On 11/25/2025, he exercised 7,021 non-qualified stock options at an exercise price of $15.74 per share, receiving the same number of common shares. On the same date, he sold 4,026 shares of common stock at a weighted average price of $27.8106 per share, with individual sale prices ranging from $27.81 to $27.83. Following these transactions, he directly beneficially owned 37,061 shares of QuidelOrtho common stock.
QuidelOrtho Corp (QDEL) filed a Form 4 reporting that its Chief Financial Officer, Joseph M. Busky, acquired company stock. On 11/24/2025, a trust for his benefit purchased 4,770 shares of QuidelOrtho common stock at a price of $26.0598 per share in an open-market transaction coded as a purchase. Following this trade, he beneficially owns 6,920 shares indirectly through the trust and 31,427 shares directly.
QuidelOrtho Corp (QDEL) director Mary Lake Polan reported an open-market purchase of company stock. On 11/21/2025, she bought 1,000 shares of common stock at a price of $22.43 per share in a transaction coded "P" for purchase. After this trade, she beneficially owns 12,640 shares directly and 17,353 shares indirectly through an LLC. The filing is a Form 4, which discloses changes in insider ownership.
QuidelOrtho Corporation reported insider equity activity for its Chief Legal Officer, Michelle A. Hodges. On November 18, 2025, 5,349 restricted stock units converted into the same number of common shares at $0 per share. On the same date, 2,717 common shares were disposed of at $21.28 per share to cover tax withholding obligations related to this vesting.
After these transactions, Hodges beneficially owned 32,035 shares of QuidelOrtho common stock directly and held 10,698 restricted stock units. Of these units, 5,349 shares vested on November 18, 2025 and the remaining 10,698 are scheduled to vest in equal installments on November 18, 2026 and November 18, 2027.
QuidelOrtho Corp (QDEL) reported an insider share purchase by its President and CEO, Brian J. Blaser. On 11/19/2025, he purchased 23,500 shares of common stock at a weighted average price of $21.3437 per share, with individual trade prices ranging from $20.91 to $21.72. After this transaction, he beneficially owned 29,533 shares indirectly through a trust and 11,451 shares directly. He also undertook to provide, upon request, detailed breakdowns of the number of shares purchased at each separate price.
QuidelOrtho Corporation furnished a stockholder letter via an 8-K. The letter from President and CEO Brian J. Blaser provides an update on results for the third quarter ended September 28, 2025 and is included as Exhibit 99.1.
The information, including Exhibit 99.1, is being furnished and is not deemed “filed” under the Exchange Act, which means it is not subject to Section 18 liability and is not incorporated by reference into other filings. The report was signed by CFO Joseph M. Busky. QuidelOrtho’s common stock trades on Nasdaq under the symbol QDEL.
QuidelOrtho Corporation reported a quarterly net loss of $733.0 million, largely due to a non-cash goodwill impairment of $700.7 million that eliminated all remaining goodwill. Total revenues were $699.9 million, down from $727.1 million a year ago, as lower Point of Care sales offset growth in Labs and Immunohematology.
Operating results reflected $39.6 million of restructuring, $47.7 million of intangible amortization, and $46.1 million in net interest expense. Year-to-date, the company recorded a net loss of $1,001.1 million and used $26.7 million in operating cash.
QuidelOrtho refinanced its capital structure on August 21, 2025, entering a new Credit Agreement with a $1.15B Term Loan A, $1.45B Term Loan B, and a $700.0M revolver; it repaid prior facilities and ended the quarter with $2.66B in total borrowings and $98.1 million in cash. Segment revenue was led by Labs $373.8M and Point of Care $164.6M. A final judgment related to a supplier dispute required payment of $10.8 million.
QuidelOrtho Corporation furnished an 8-K announcing its financial results for the third quarter ended September 28, 2025, and an earnings conference call. The company will host the call at 2:00 p.m. Pacific Time on November 5, 2025. A press release with the results is furnished as Exhibit 99.1. The information is furnished and not deemed filed under the Exchange Act.
QuidelOrtho (QDEL) reported insider equity activity by EVP of R&D & CTO Jonathan P. Siegrist. On 10/15/2025, 18,656 restricted stock units converted into common stock at $0 per unit. To cover taxes, 6,676 shares were withheld by the issuer at a price of $27.31.
Following these transactions, Siegrist directly holds 11,980 shares of common stock. He also holds 37,314 RSUs that will vest in equal installments on October 15, 2026 and October 15, 2027. Each RSU represents the right to receive one share of QuidelOrtho common stock.